FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira

On Oct. 15, the U.S. Food & Drug Administration (FDA) approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to and interchangeable with (i.e, may be substituted for) its reference product Humira (adalimumab) for Cyltezo’s approved uses. Cyltezo is the second interchangeable biosimilar... [Read More]

Source: The Rheumatologist - October 19, 2021 Category: Rheumatology Authors: U.S. Food & Drug Administration Tags: Biologics & Biosimilars Drug Updates adalimumab adalimumab-adbm Cyltezo FDA approval Humira U.S. Food and Drug Administration (FDA) Source Type: research